1. Home
  2. NAII vs IGC Comparison

NAII vs IGC Comparison

Compare NAII & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAII
  • IGC
  • Stock Information
  • Founded
  • NAII 1980
  • IGC 2005
  • Country
  • NAII United States
  • IGC United States
  • Employees
  • NAII N/A
  • IGC N/A
  • Industry
  • NAII Medicinal Chemicals and Botanical Products
  • IGC Biotechnology: Pharmaceutical Preparations
  • Sector
  • NAII Health Care
  • IGC Health Care
  • Exchange
  • NAII Nasdaq
  • IGC Nasdaq
  • Market Cap
  • NAII 18.6M
  • IGC 20.2M
  • IPO Year
  • NAII 1987
  • IGC N/A
  • Fundamental
  • Price
  • NAII $3.43
  • IGC $0.31
  • Analyst Decision
  • NAII
  • IGC Strong Buy
  • Analyst Count
  • NAII 0
  • IGC 2
  • Target Price
  • NAII N/A
  • IGC $3.88
  • AVG Volume (30 Days)
  • NAII 5.0K
  • IGC 213.7K
  • Earning Date
  • NAII 05-14-2025
  • IGC 06-23-2025
  • Dividend Yield
  • NAII N/A
  • IGC N/A
  • EPS Growth
  • NAII N/A
  • IGC N/A
  • EPS
  • NAII N/A
  • IGC N/A
  • Revenue
  • NAII $125,483,000.00
  • IGC $1,236,000.00
  • Revenue This Year
  • NAII N/A
  • IGC N/A
  • Revenue Next Year
  • NAII N/A
  • IGC $16.45
  • P/E Ratio
  • NAII N/A
  • IGC N/A
  • Revenue Growth
  • NAII 4.39
  • IGC 1.65
  • 52 Week Low
  • NAII $2.57
  • IGC $0.25
  • 52 Week High
  • NAII $6.88
  • IGC $0.55
  • Technical
  • Relative Strength Index (RSI)
  • NAII 61.23
  • IGC 48.79
  • Support Level
  • NAII $3.20
  • IGC $0.30
  • Resistance Level
  • NAII $3.42
  • IGC $0.33
  • Average True Range (ATR)
  • NAII 0.08
  • IGC 0.02
  • MACD
  • NAII 0.01
  • IGC -0.00
  • Stochastic Oscillator
  • NAII 83.52
  • IGC 13.20

About NAII Natural Alternatives International Inc.

Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Share on Social Networks: